Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus PREDNISONE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus PREDNISONE INTENSOL.
ASMANEX HFA vs PREDNISONE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
5-60 mg orally once daily or divided twice daily, titrated to response.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
2-4 hours (terminal) for prednisone; prednisolone half-life 2-4 hours. Clinical context: shorter than anti-inflammatory effect due to delayed receptor-mediated action.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal: <30% unchanged; major metabolites (prednisolone, 20-dihydroprednisolone) conjugated and excreted in urine. Fecal: <10%.
Category C
Category D/X
Corticosteroid, Inhaled
Corticosteroid